• Join
  • Login
  • Contact

Search abstracts

The impact of IV Indomethacin Use on the total Serum Bilirubin Levels of very low birth weight Neonates

  • At: 2016 FIP Congress in Buenos Aires (Argentina)
  • Type: Poster
  • By: HUANG, Chin-Shing (Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Department of Pharmacy, Kaohsiung, China Taiwan)
  • Co-author(s): Chin-Shing Huang:|Chih-Chiang Tai:|Ching-Ling Tai:|Zon-Min Lee:
  • Abstract:

      Ceftriaxone and sulfisoxazole are known to be contraindicated for use in neonates with hyperbilirubinemia due to their high protein-binding ability and daily doses. However, indomethacin, with very high protein-binding ability (99%), is commonly used for the treatment of patent ductus arteriosus in very low birth weight (VLBW) neonates.



  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses